Impacts of spironolactone on albuminuria in patients with diabetic nephropathy and hypertensio
Phase 4
- Conditions
- Diabetic nephropathy
- Registration Number
- JPRN-UMIN000008016
- Lead Sponsor
- Department of Nephrology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1.History of using Spironolactone within 6 months 2.Type 1 diabetes 3.Uncontrolled Hypertension (systolic BP>180mmHg, diastolic>110mmHg) 4. Bilateral renal artery stenosis or renal artery stenosis with unilateral kidney 5.Myocardial infarction, unstable angina and stroke in the past 3 months 6. Heart failure (NYHA 3 or4 ) 7. Potassium > 5.0 mEq/L 8. Cancer 9. liver dysfunction (AST or ALT >100 IU/L) 10. History of renal deterioration under ACE inhibitors/ARBs 11. Pregnancy and lactation 12. Unwillingness of entry 13. Patients with contraindication to study drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of albuminuria
- Secondary Outcome Measures
Name Time Method 1.changes of serum potassium 2.changes of serum Cr, cystatin C, eGFR 3.changes of urinary iso-prostaglandin F2a 4.influences of TTKG 5.changes of serum and urinary CD147 6. changes of serum hs-CRP